|
|
Volumn 95, Issue 23, 2003, Pages 1744-1746
|
|
For investigational targeted drugs, combination trials pose challenges
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
BORTEZOMIB;
CANCER VACCINE;
CETUXIMAB;
ERLOTINIB;
GELDANAMYCIN;
PROVENGE;
RITUXIMAB;
THALIDOMID;
THALIDOMIDE;
TRASTUZUMAB;
ANTINEOPLASTIC ACTIVITY;
BREAST CANCER;
CANCER COMBINATION CHEMOTHERAPY;
CLINICAL TRIAL;
COLON CANCER;
DRUG APPROVAL;
DRUG CHOICE;
DRUG EFFICACY;
DRUG MARKETING;
DRUG SAFETY;
DRUG TARGETING;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
KIDNEY CANCER;
LUNG ADENOCARCINOMA;
LUNG NON SMALL CELL CANCER;
LYMPHOMA;
MULTIPLE MYELOMA;
NOTE;
PRIORITY JOURNAL;
PROSTATE CANCER;
|
|
EID: 0347519171
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/95.23.1744 Document Type: Note |
|
Times cited : (19)
|
|
References (0)
|